3.81 USD
▲+0.03+0.79%
盘后 3.83 +0.65%
2026-11-19
市值
$1.34B
市盈率
—
EPS
-0.39
股息率
—
52 周区间
3.71 – 9.75
成交量
9.93M
Beta
1.73
目标价
12.45
52W 低 3.7152W 高 9.75
价格走势
公司简介
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua...